The Company periodically acquires the operating assets and liabilities of dialysis centers. The results of operations for these acquisitions are included in the Company’s Consolidated Statements of Operations from their respective acquisition consummation dates.

The consideration transferred, on a combined basis for all acquisitions consummated during 2019 through the date of issuance of these financial statements, was as follows:

The amounts recognized as of the acquisition date, on a combined basis for all acquisitions consummated during 2019 through the date of issuance of these financial statements, for each major class of assets acquired and liabilities assumed were allocated preliminarily based on the estimated fair value, as follows:



Property and equipment	$	1,232
Noncompete agreements	660
Goodwill	9,108
Other assets	245
Total consideration paid	$	11,245

The acquisitions were made to expand the Company’s market presence in the indicated locations. The goodwill arising from these acquisitions was primarily attributable to future growth opportunities and any intangible assets that did not qualify for separate recognition, and goodwill of $4,774 is expected to be deductible for tax purposes. Pro forma information is not presented because the impact on results of operations is not significant.

This acquisition was made to expand the Company’s market presence in California. Pro forma information is not presented because impact on results of operations is not significant.

On November 1, 2017, the Company acquired a majority interest in the assets of two separate dialysis centers in Oklahoma.

The cash consideration paid, on a combined basis for all acquisitions consummated during 2017, was allocated based on the estimated fair value, as follows:



Property and equipment	$	737
Noncompete agreements and other intangible assets	93
Goodwill	725
Cash consideration paid	$	1,555

These acquisitions were made to expand the Company’s market presence in the indicated locations. The goodwill arising from these acquisitions is primarily attributable to future growth opportunities and any intangible assets that did not qualify for separate recognition, and $647 of the goodwill was deductible for tax purposes. These acquisitions, individually and in the aggregate, had an immaterial impact on the results of operations in the year of acquisition. Pro forma information is not presented because impact on results of operations is not significant.

The Company periodically divests the operating assets and liabilities of dialysis centers. The results of operations for these divestitures are included in the Company’s Consolidated Statements of Operations through their respective sale consummation dates.

On March 1, 2019, the Company sold 100% of the Company’s equity in two dialysis clinics in Florida and received a combined cash consideration for the sales of $3,300. The transactions resulted in the recognition of a combined gain of $512, which is included as a reduction to general and administrative expenses to arrive at operating income in the Consolidated Statements of Operations for the year ended December 31, 2019, and a reduction of goodwill of $2,210.

On July 1, 2019, the Company sold 100% of the Company’s equity in two dialysis clinics in Maryland and received a combined cash consideration for the sales of $3,000. The transactions resulted in the recognition of a combined loss of $228, which is included as an increase to general and administrative expenses to arrive at operating income in the Consolidated Statements of Operations for the year ended December 31, 2019, and a reduction of goodwill of $2,155.

On March 1, 2018, the Company sold 100% of its equity in a dialysis clinic in Florida and received cash consideration for the sale of $2,500. The transaction resulted in the recognition of a gain of $262 related to the sale of the clinic and its derecognition which is included as a reduction to general and administrative expenses to arrive at operating income in the Consolidated Statements of Operations for the year ended December 31, 2018 and a reduction of goodwill of $1,806.

On June 2, 2017, the Company sold 100% of its equity in a dialysis clinic in Massachusetts and on August 1, 2017, the Company sold 100% of its equity in a dialysis clinic in Florida for a combined cash consideration of $1,075. The transactions resulted in the recognition of a combined gain of $615 related to the sale of the clinics and their derecognition which is included as a reduction to general and administrative expenses to arrive at operating income in the Consolidated Statements of Operations for the year ended December 31, 2018 and a reduction of goodwill of $563.